Ocular manifestations of liver disease: an important diagnostic aid
ConclusionsBuilding strong associations between ocular and liver pathology will allow for early detection of such conditions, leading to the early implementation of management strategies. While this review outlines several of the existing connections between hepatic and ophthalmic disease, further research is needed in the area in order to strengthen these associations. (Source: International Ophthalmology)
Source: International Ophthalmology - April 15, 2024 Category: Opthalmology Source Type: research
Longitudinal changes in bone mineral density may be associated with long-term survival in patients with cirrhosis: A proof of concept of study
ConclusionAmong body composition parameters, changes in bone mineral density correlate best with survival and have prognostic relevance similar to that of ascites and MELD score.Graphical Abstract (Source: Indian Journal of Gastroenterology)
Source: Indian Journal of Gastroenterology - April 15, 2024 Category: Gastroenterology Source Type: research
Organizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration
ConclusionsResources, barriers, and care processes varied across diverse VAMCs. Smaller VAMCs without specialty care achieved HCC and EVST surveillance rates nearly as high as more complex and resourced VAMCs if they used a population management tool to identify the patients due for cirrhosis care. (Source: Digestive Diseases and Sciences)
Source: Digestive Diseases and Sciences - April 14, 2024 Category: Gastroenterology Source Type: research
Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
Diagnostics (Basel). 2024 Mar 29;14(7):725. doi: 10.3390/diagnostics14070725.ABSTRACTLC-SPIK is a liver cancer-specific isoform of Serine Protease Inhibitor Kazal and has been proposed as a new biomarker for the detection of HCC given its unique 3D structure, which differs from normal pancreatic SPIK. An ELISA technology based on its unique structure was developed to use LC-SPIK as an effective biomarker for the clinical diagnosis of HCC. AFP, the most widely used biomarker for HCC surveillance currently, suffers from poor clinical performance, especially in the detection of early-stage HCC. In one case-control study, whic...
Source: Cancer Control - April 13, 2024 Category: Cancer & Oncology Authors: Felix Lu Connor Ott Prabha Bista Xuanyong Lu Source Type: research
Application of Antithrombotic Drugs in Different Age-Group Patients with Upper Gastrointestinal Bleeding
CONCLUSIONS: In UGIB patients, a history of antiplatelet or antithrombotic drugs and the use of antiplatelet drugs after UGIB did not affect the patient's prognosis. In elderly UGIB patients, although antithrombotic drugs did not increase the risk of death, the increased risk of rebleeding after resumption of use deserved careful treatment. It was safe to recover anticoagulant drugs as soon as possible in young UGIB patients.PMID:38606387 | PMC:PMC11008970 | DOI:10.1155/2024/1710708 (Source: Gastroenterology Research and Practice)
Source: Gastroenterology Research and Practice - April 12, 2024 Category: Gastroenterology Authors: Ding Peng Huihong Zhai Source Type: research
Tyrosine hydroxylase inhibits HCC progression by downregulating TGF β/Smad signaling
AbstractThe alteration of metabolic processes has been found to have significant impacts on the development of hepatocellular carcinoma (HCC). Nevertheless, the effects of dysfunction of tyrosine metabolism on the development of HCC remains to be discovered. This research demonstrated that tyrosine hydroxylase (TH), which responsible for the initial and limiting step in the bio-generation of the neuro-transmitters dopamine and adrenaline, et al. was shown to be reduced in HCC. Increased expression of TH was found facilitates the survival of HCC patients. In addition, decreased TH indicated larger tumor size, much more numb...
Source: European Journal of Medical Research - April 12, 2024 Category: Research Source Type: research
Albumin: a comprehensive review and practical guideline for clinical use
ConclusionAlbumin administration is most indicated in management of cirrhosis complications. Fluid resuscitation or treatment of severe and refractory edema, especially in patients with hypoalbuminemia and not responding to other treatments, is another rational use for albumin. Implementation of evidence-based guidelines in hospitals can be an effective measure to reduce inappropriate uses of albumin. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - April 12, 2024 Category: Drugs & Pharmacology Source Type: research
FDA Okays First Drug for Scarring From Fatty Liver Disease
The US Food and Drug Administration (FDA) recently approved resmetirom, marketed as Rezdiffra, for adults with nonalcoholic steatohepatitis (NASH) without cirrhosis. NASH is a progressive fatty liver disease that affects up to 8 million people in the US and can cause liver inflammation and scarring, known as fibrosis. Resmetirom, an oral drug that reduces the accumulation of liver fat, can be used along with diet and exercise, which are the standard care for patients with NASH. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 12, 2024 Category: General Medicine Source Type: research
Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update
Expert Opin Emerg Drugs. 2024 Apr 11. doi: 10.1080/14728214.2024.2341878. Online ahead of print.NO ABSTRACTPMID:38603460 | DOI:10.1080/14728214.2024.2341878 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - April 11, 2024 Category: Drugs & Pharmacology Authors: Jonathan A Fallowfield Maria Jimenez Ramos Source Type: research
Optimizing nutrition in hepatic cirrhosis: A comprehensive assessment and care approach
World J Gastroenterol. 2024 Mar 14;30(10):1313-1328. doi: 10.3748/wjg.v30.i10.1313.ABSTRACTCirrhosis is considered a growing cause of morbidity and mortality, which represents a significant public health problem. Currently, there is no effective treatment to reverse cirrhosis. Treatment primarily centers on addressing the underlying liver condition, monitoring, and managing portal hypertension-related complications, and evaluating the potential for liver transplantation in cases of decompensated cirrhosis, marked by rapid progression and the emergence of complications like variceal bleeding, hepatic encephalopathy, ascites...
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Osvely Mendez-Guerrero Anaisa Carranza-Carrasco Luis Alberto Chi-Cervera Aldo Torre Nalu Navarro-Alvarez Source Type: research
Optimizing nutrition in hepatic cirrhosis: A comprehensive assessment and care approach
World J Gastroenterol. 2024 Mar 14;30(10):1313-1328. doi: 10.3748/wjg.v30.i10.1313.ABSTRACTCirrhosis is considered a growing cause of morbidity and mortality, which represents a significant public health problem. Currently, there is no effective treatment to reverse cirrhosis. Treatment primarily centers on addressing the underlying liver condition, monitoring, and managing portal hypertension-related complications, and evaluating the potential for liver transplantation in cases of decompensated cirrhosis, marked by rapid progression and the emergence of complications like variceal bleeding, hepatic encephalopathy, ascites...
Source: World Journal of Gastroenterology : WJG - April 10, 2024 Category: Gastroenterology Authors: Osvely Mendez-Guerrero Anaisa Carranza-Carrasco Luis Alberto Chi-Cervera Aldo Torre Nalu Navarro-Alvarez Source Type: research
